Two Sigma Advisers LP Sells 24,300 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Two Sigma Advisers LP lowered its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 22.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 81,700 shares of the specialty pharmaceutical company's stock after selling 24,300 shares during the period. Two Sigma Advisers LP owned about 0.14% of Jazz Pharmaceuticals worth $10,061,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. LSV Asset Management grew its holdings in shares of Jazz Pharmaceuticals by 1.5% in the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock worth $311,699,000 after acquiring an additional 37,108 shares during the period. Pacer Advisors Inc. grew its holdings in shares of Jazz Pharmaceuticals by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after acquiring an additional 115,102 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after acquiring an additional 320,724 shares during the period. Capital World Investors grew its holdings in shares of Jazz Pharmaceuticals by 5.7% in the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock worth $236,860,000 after acquiring an additional 104,195 shares during the period. Finally, Ameriprise Financial Inc. grew its holdings in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after purchasing an additional 315,608 shares during the period. Institutional investors own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total value of $937,625.00. Following the sale, the chief executive officer now directly owns 464,058 shares in the company, valued at approximately $66,940,366.50. This represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 1,140 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the sale, the chief accounting officer now owns 7,012 shares in the company, valued at approximately $966,323.72. The trade was a 13.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,236 shares of company stock worth $3,956,190. 4.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have issued reports on JAZZ. UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price target for the company from $145.00 to $179.00 in a report on Friday, March 7th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their price target for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. HC Wainwright boosted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a report on Monday, March 10th. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $182.79.

Jazz Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ:JAZZ traded down $1.70 during trading on Wednesday, hitting $107.77. The company had a trading volume of 166,795 shares, compared to its average volume of 850,652. The stock has a market cap of $6.64 billion, a price-to-earnings ratio of 15.18, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The company has a fifty day simple moving average of $111.57 and a two-hundred day simple moving average of $121.78. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. Jazz Pharmaceuticals's revenue for the quarter was down .5% on a year-over-year basis. During the same period in the previous year, the business earned $2.68 earnings per share. As a group, equities analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.